OneSource Specialty Pharma Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹17.8K Cr
OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue. OneSource Specialty Pharma projects a revenue of $400 million in the next 3 to 4 years, growing at a CAGR of 25-30%.
From OneSource Specialty Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,535
Market Cap
₹17.8K Cr
How does OneSource Specialty Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare OneSource Specialty Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹428 Cr, net profit ₹5 Cr.
Full financials →📊 Revenue & Sales Performance
- →OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue.
- →GLP-1 cartridge capacity to increase 5x from 40 million to 220 million units by 2028.
- →Expansion driven by new product approvals and increasing demand in emerging markets like Brazil, India, and China.
- →Commercial sales (CSA) expected to grow from 20% to 80% of volumes by FY27.
- →Anticipates a steady-state, predictable commercial business beyond FY27 with more than 40% EBITDA margins.
- →Strong customer base with 20 GLP-1 customers and 60+ overall, supporting expanded capacity.
- →New capacities to come online gradually from FY26 onwards, with expected revenue ramp-up in H2 FY26.
- →Biologics business to commercialize more substantially after 3-4 years, offering long-term growth beyond the current guidance period.
📈 Profitability & Margins
- →OneSource Specialty Pharma projects a revenue of $400 million in the next 3 to 4 years, growing at a CAGR of 25-30%.
- →EBITDA margins are expected to be very strong, targeted at around 40%.
- →EPS for the recent quarter stood at INR 7.8 (fully diluted).
- →Return on capital employed (ROCE) is in the mid-30% range and trending positively.
- →Management is confident in achieving commitments on growth, EBITDA, and ROCE over 3-4 years.
- →The company expects steady quarter-on-quarter business growth beyond FY27.
- →Cash flow generation is projected to be significant with capex funded largely from internal accruals, supporting further expansion without borrowing.
- →The EBITDA margin range for FY26 is guided to be consistent with the current quarter (~36%), with some quarterly fluctuations expected.
🏗️ Capital Expenditure Plans
- →OneSource Specialty Pharma plans to invest about $100 million in capex over the next 2 to 4 years.
- →A significant part of this capex will be towards expanding drug-device combination (DDC) capacities.
- →Additional investments will be made to add new capabilities in the injectable space.
- →The company is proactively expanding capacities to meet growing customer demand, especially in the GLP-1 segment, increasing capacity from 40 million to 220 million units over 3 to 4 years.
- →Some customers participate in the capex program, contributing to capacity reservation fees, sharing risk with OneSource.
- →The capex will be primarily funded from internal accruals and proceeds from a recent capital raise.
- →The company sees the expansion as essential for capitalizing on future opportunities and increasing revenue up to $400 million within 3-4 years.
💰 Fundraising & Capital Structure
- →The company raised about INR 801 crores (~$100 million) recently, using half of it to retire high-cost and guarantee-backed debt.
- →They anticipate significant cash generation and customer participation to support the $100 million planned capex over the next 2-4 years.
- →The company aims to fund capex primarily from internal accruals and customer participation (reservation capacity fees), thus minimizing the need to borrow.
- →Current debt to EBITDA ratio is healthy, with plans to be debt-free by the end of FY 2027.
- →No explicit mention of any immediate plans for new fundraising through debt or equity beyond the recent capital raise.
- →The focus is on efficient use of internal cash flows along with partner risk-sharing for future investments.
📋 Order Book & Pipeline
- →OneSource has customers providing reservation fees to block dedicated capacity.
- →Customers have given forecasts ranging from 24 to 36 months, with 12 to 18 months being binding forecasts, equivalent to "take or pay" arrangements.
- →The company proactively expands capacity to support customer demand.
- →Current capacity of 40 million units is insufficient; plans are to increase capacity 5x to approximately 220 million units over 3 to 4 years.
- →Strong demand and robust forecasts from 20 leading generic players, many of whom have significant market share.
- →Capacity expansion is backed by customer participation through reservation fees, mitigating investment risks.
- →The expected ramp-up aligns with markets coming off patent and growing demand for GLP-1 products globally.
Key Metrics
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q3 FY25 results?
OneSource targets 25%-30% CAGR growth over the next 3-4 years, aiming for $400 million revenue. OneSource Specialty Pharma projects a revenue of $400 million in the next 3 to 4 years, growing at a CAGR of 25-30%.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
OneSource Specialty Pharma plans to invest about $100 million in capex over the next 2 to 4 years.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.